Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 88 articles:
HTML format

Single Articles

    May 2024
  1. CLEGG LE, Stepanov O, Schmidt H, Tang W, et al
    Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Antimicrob Agents Chemother. 2024;68:e0158723.
    PubMed     Abstract available

    April 2024
  2. CHESNOKOV A, Ivashchenko AA, Matsuzaki Y, Takashita E, et al
    Influenza C virus susceptibility to antivirals with different mechanisms of action.
    Antimicrob Agents Chemother. 2024 Apr 8:e0172723. doi: 10.1128/aac.01727.
    PubMed     Abstract available

  3. XU S, Esmaeili S, Cardozo-Ojeda EF, Goyal A, et al
    Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents.
    Antimicrob Agents Chemother. 2024;68:e0101523.
    PubMed     Abstract available

  4. TANG W-F, Chang Y-H, Lin C-C, Jheng J-R, et al
    BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Antimicrob Agents Chemother. 2024;68:e0095623.
    PubMed     Abstract available

    March 2024
  5. YU Y, Chen S, Zhang H, Duan Y, et al
    A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection.
    Antimicrob Agents Chemother. 2024 Mar 12:e0135023. doi: 10.1128/aac.01350.
    PubMed     Abstract available

  6. MIAH M, Davis AM, Hannoun C, Said JS, et al
    Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.
    Antimicrob Agents Chemother. 2024;68:e0106423.
    PubMed     Abstract available

  7. ZHANG R, Zhou J, Yan H, Liu X, et al
    Manidipine is not a potential inhibitor against SARS-CoV-2 main protease.
    Antimicrob Agents Chemother. 2024;68:e0129723.

    February 2024
  8. PLOTNIK D, Sager JE, Aryal M, Fanget MC, et al
    A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
    Antimicrob Agents Chemother. 2024 Feb 20:e0127323. doi: 10.1128/aac.01273.
    PubMed     Abstract available

    January 2024
  9. YANG H, Yu X, Hou W, Liu X, et al
    Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
    Antimicrob Agents Chemother. 2024 Jan 30:e0138423. doi: 10.1128/aac.01384.
    PubMed     Abstract available

  10. BAKER J, Ombredane H, Daly L, Knowles I, et al
    Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice.
    Antimicrob Agents Chemother. 2024;68:e0105023.
    PubMed     Abstract available

  11. STRIZKI JM, Gaspar JM, Howe JA, Hutchins B, et al
    Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Antimicrob Agents Chemother. 2024;68:e0095323.
    PubMed     Abstract available

    December 2023
  12. ZHANG H, Zhou J, Chen H, Mao J, et al
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    PubMed     Abstract available

    November 2023
  13. TONG X, Keung W, Arnold LD, Stevens LJ, et al
    Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
    Antimicrob Agents Chemother. 2023;67:e0084023.
    PubMed     Abstract available

    July 2023
  14. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Ferris M, et al
    Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
    Antimicrob Agents Chemother. 2023;67:e0026623.
    PubMed     Abstract available

    April 2023
  15. DE LEON P, Canas-Arranz R, Bustos MJ, Saiz M, et al
    Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.
    Antimicrob Agents Chemother. 2023;67:e0170322.
    PubMed     Abstract available

    March 2023
  16. ZHANG D, Zhao Y, You X, He S, et al
    Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection.
    Antimicrob Agents Chemother. 2023;67:e0148722.
    PubMed     Abstract available

  17. LIU STH, Mirceta M, Lin G, Anderson DM, et al
    Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.
    Antimicrob Agents Chemother. 2023;67:e0151422.
    PubMed     Abstract available

    February 2023
  18. GARCIA A, Huh EY, Lee SC
    Serine/Threonine Phosphatase Calcineurin Orchestrates the Intrinsic Resistance to Micafungin in the Human-Pathogenic Fungus Mucor circinelloides.
    Antimicrob Agents Chemother. 2023;67:e0068622.
    PubMed     Abstract available

    January 2023
  19. SOMOVILLA P, Garcia-Crespo C, Martinez-Gonzalez B, Soria ME, et al
    Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin.
    Antimicrob Agents Chemother. 2023;67:e0131522.
    PubMed     Abstract available

  20. ZUMBRUN EE, Kaku CI, Dillinger L, Zak SE, et al
    Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19.
    Antimicrob Agents Chemother. 2023;67:e0135322.
    PubMed     Abstract available

  21. KIM YS, Jeon SH, Kim J, Koh JH, et al
    A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.
    Antimicrob Agents Chemother. 2023;67:e0045222.
    PubMed     Abstract available

    December 2022
  22. KIM TY, Jeon S, Ko M, Du YE, et al
    Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern.
    Antimicrob Agents Chemother. 2022;66:e0120122.
    PubMed     Abstract available

  23. SAKE SM, Kosch C, Blockus S, Haid S, et al
    Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages.
    Antimicrob Agents Chemother. 2022;66:e0103222.
    PubMed     Abstract available

    October 2022
  24. LINGSCHEID T, Kinzig M, Kruger A, Muller N, et al
    Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Antimicrob Agents Chemother. 2022 Oct 26:e0122922. doi: 10.1128/aac.01229.
    PubMed     Abstract available

  25. MUKAE H, Yotsuyanagi H, Ohmagari N, Doi Y, et al
    A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
    Antimicrob Agents Chemother. 2022;66:e0069722.
    PubMed     Abstract available

  26. SHIMIZU R, Sonoyama T, Fukuhara T, Kuwata A, et al
    Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Antimicrob Agents Chemother. 2022;66:e0063222.
    PubMed     Abstract available

  27. RAMBACH G, Striednig B, Neurauter M, Hermann M, et al
    Indications that the Antimycotic Drug Amphotericin B Enhances the Impact of Platelets on Aspergillus.
    Antimicrob Agents Chemother. 2022 Oct 3:e0068122. doi: 10.1128/aac.00681.
    PubMed     Abstract available

    August 2022
  28. LAPAILLERIE D, Charlier C, Guyonnet-Duperat V, Murigneux E, et al
    Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
    Antimicrob Agents Chemother. 2022;66:e0008322.
    PubMed     Abstract available

    July 2022
  29. RODVOLD KA, Gotfried MH, Gupta V, Ek A, et al
    Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.
    Antimicrob Agents Chemother. 2022;66:e0059022.
    PubMed     Abstract available

  30. WATSON JA, Kissler SM, Day NPJ, Grad YH, et al
    Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies.
    Antimicrob Agents Chemother. 2022;66:e0019222.
    PubMed     Abstract available

  31. CHECKMAHOMED L, Carbonneau J, Du Pont V, Riola NC, et al
    In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022;66:e0019822.
    PubMed     Abstract available

  32. ICHO S, Rujas E, Muthuraman K, Tam J, et al
    Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
    Antimicrob Agents Chemother. 2022;66:e0043922.
    PubMed     Abstract available

  33. ATMAR RL, Finch N
    New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2022 Jul 12:e0240421. doi: 10.1128/aac.02404.
    PubMed     Abstract available

    June 2022
  34. LEEGWATER E, Moes DJAR, Bosma LBE, Ottens TH, et al
    Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
    Antimicrob Agents Chemother. 2022;66:e0025422.
    PubMed     Abstract available

  35. PITTS J, Li J, Perry JK, Du Pont V, et al
    Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Antimicrob Agents Chemother. 2022;66:e0022222.
    PubMed     Abstract available

    March 2022
  36. DONG R, Jiang L, Yang T, Wang C, et al
    Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.
    Antimicrob Agents Chemother. 2022;66:e0204521.
    PubMed     Abstract available

  37. CHEN J, Dai L, Kendrick S, Post SR, et al
    The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways.
    Antimicrob Agents Chemother. 2022;66:e0239521.
    PubMed     Abstract available

  38. PARK AYJ, Tran DQ, Schaal JB, Wang M, et al
    Preclinical Pharmacokinetics and Safety of Intravenous RTD-1.
    Antimicrob Agents Chemother. 2022;66:e0212521.
    PubMed     Abstract available

  39. BAGHDADI J, Bejo S, Harris A
    Reply to Casalini et al., "Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution".
    Antimicrob Agents Chemother. 2022;66:e0233221.

  40. CASALINI G, Pozza G, Giacomelli A, Antinori S, et al
    Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution.
    Antimicrob Agents Chemother. 2022;66:e0229621.

  41. HICKERSON BT, Adams SE, Barman S, Miller L, et al
    Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.
    Antimicrob Agents Chemother. 2022 Mar 9:e0000922. doi: 10.1128/aac.00009.
    PubMed     Abstract available

    February 2022
  42. MERCHANTE N, Carcel S, Garrido-Gracia JC, Trigo-Rodriguez M, et al
    Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.
    Antimicrob Agents Chemother. 2022;66:e0210721.
    PubMed     Abstract available

  43. MEUNIER T, Desmarets L, Bordage S, Bamba M, et al
    A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses.
    Antimicrob Agents Chemother. 2022;66:e0158121.
    PubMed     Abstract available

    January 2022
  44. DINESH KUMAR N, Ter Ellen BM, Bouma EM, Troost B, et al
    Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells.
    Antimicrob Agents Chemother. 2022;66:e0154321.
    PubMed     Abstract available

    November 2021
  45. TIETJEN I, Cassel J, Register ET, Zhou XY, et al
    The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants.
    Antimicrob Agents Chemother. 2021;65:e0077221.
    PubMed     Abstract available

    October 2021
  46. BAGHDADI JD, Coffey KC, Adediran T, Goodman KE, et al
    Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.
    Antimicrob Agents Chemother. 2021;65:e0134121.
    PubMed     Abstract available

  47. LI Y, Qi L, Bai H, Sun C, et al
    Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
    Antimicrob Agents Chemother. 2021;65:e0106321.
    PubMed     Abstract available

    September 2021
  48. SCHOOLEY RT, Carlin AF, Beadle JR, Valiaeva N, et al
    Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
    Antimicrob Agents Chemother. 2021;65:e0115521.
    PubMed     Abstract available

  49. SHAH S, Ackley TW, Topal JE
    Renal and Hepatic Toxicity Analysis of Remdesivir Formulations: Does What Is on the Inside Really Count?
    Antimicrob Agents Chemother. 2021;65:e0104521.
    PubMed     Abstract available

  50. YAN VC, Muller FL
    Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.
    Antimicrob Agents Chemother. 2021;65:e0111721.
    PubMed     Abstract available

    August 2021
  51. PASCUA PNQ, Jones JC, Marathe BM, Seiler P, et al
    Baloxavir treatment delays influenza B virus transmission in ferrets and results in limited generation of drug-resistant variants.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0113721. doi: 10.1128/AAC.01137.
    PubMed     Abstract available

  52. GABORIT B, Dailly E, Vanhove B, Josien R, et al
    Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
    Antimicrob Agents Chemother. 2021;65:e0123721.
    PubMed     Abstract available

  53. LI R, Liclican A, Xu Y, Pitts J, et al
    Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells.
    Antimicrob Agents Chemother. 2021;65:e0060221.
    PubMed     Abstract available

  54. GAMMELTOFT KA, Zhou Y, Duarte Hernandez CR, Galli A, et al
    Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0268020.
    PubMed     Abstract available

  55. HANSON BM, Dinh AQ, Tran TT, Arenas S, et al
    Candida auris Invasive Infections During a COVID-19 Case Surge.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0114621. doi: 10.1128/AAC.01146.
    PubMed     Abstract available

    July 2021
  56. GOMIS-FONT MA, Pitart C, Del Barrio-Tofino E, Zboromyrska Y, et al
    Emergence of Resistance to Novel Cephalosporin-beta-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
    Antimicrob Agents Chemother. 2021;65:e0008921.
    PubMed     Abstract available

  57. LIMONTA D, Dyna-Dagman L, Branton W, Mancinelli V, et al
    Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65:e0049121.
    PubMed     Abstract available

  58. WU X, Li N, Wang G, Liu W, et al
    Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Antimicrob Agents Chemother. 2021;65:e0035021.
    PubMed     Abstract available

    June 2021
  59. MANTLO EK, Paessler S, Seregin A, Mitchell A, et al
    Luminore CopperTouch Surface Coating Effectively Inactivates SARS-CoV-2, Ebola Virus, and Marburg Virus In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0139020.
    PubMed     Abstract available

  60. RAMIREZ S, Fernandez-Antunez C, Galli A, Underwood A, et al
    Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
    Antimicrob Agents Chemother. 2021;65:e0009721.
    PubMed     Abstract available

    May 2021
  61. WANG L, Zhu Q, Xiang K, Zhang Y, et al
    Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available

    March 2021
  62. MENGUAL-CHULIA B, Alonso-Cordero A, Cano L, Del Mar Mosquera M, et al
    Surveillance of Influenza A resistance to polymerase complex inhibitors by whole genome analysis, 2016-17, 2017-18 and 2018-19 Seasons, Eastern Spain.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.02718.
    PubMed     Abstract available

  63. YAN VC, Muller FL
    Remdesivir for COVID-19: Why Not Dose Higher?
    Antimicrob Agents Chemother. 2021;65.

  64. DORGHAM K, Neumann AU, Decavele M, Luyt CE, et al
    Considering Personalized Interferon Beta Therapy for COVID-19.
    Antimicrob Agents Chemother. 2021;65.

  65. JUNEJA K, Humeniuk R, Porter D, Cao H, et al
    Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?"
    Antimicrob Agents Chemother. 2021;65.

    Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".
    Antimicrob Agents Chemother. 2021;65.

  67. GOOD SS, Westover J, Jung KH, Zhou XJ, et al
    AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available

  68. KUO CJ, Chao TL, Kao HC, Tsai YM, et al
    Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available

  69. MAY M, Chang M, Dietz D, Shoucri S, et al
    Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available

  70. TOMITA Y, Takeda M, Matsuyama S
    The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
    Antimicrob Agents Chemother. 2021 Mar 1. pii: AAC.00020.
    PubMed     Abstract available

    February 2021
    Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.

    Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management.
    Antimicrob Agents Chemother. 2021;65.

  73. TE VELTHUIS AJW, Zubkova TG, Shaw M, Mehle A, et al
    Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02605.
    PubMed     Abstract available

    Plitidepsin: a repurposed drug for the treatment of COVID-19.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.00200.
    PubMed     Abstract available

    January 2021
  75. XU Y, Barauskas O, Kim C, Babusis D, et al
    Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available

  76. ACKLEY TW, McManus D, Topal JE, Cicali B, et al
    A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available

    December 2020
  77. ALEISSA MM, Silverman EA, Paredes Acosta LM, Nutt CT, et al
    New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
    Antimicrob Agents Chemother. 2020;65.
    PubMed     Abstract available

  78. VANDERLINDEN E, Van Winkel N, Naesens L, Van Damme EJM, et al
    In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA and UDA as Inhibitors of Influenza a and B Virus Replication.
    Antimicrob Agents Chemother. 2020 Dec 7. pii: AAC.01732.
    PubMed     Abstract available

    November 2020
  79. SUZUKI S, Nguyen CT, Ogata-Nakahara A, Shibata A, et al
    Efficacy of a cap-dependent endonuclease inhibitor and neuraminidase inhibitors against H7N9 highly pathogenic avian influenza virus causing severe viral pneumonia in cynomolgus macaques.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01825.
    PubMed     Abstract available

    Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available

  81. YAN VC, Muller FL
    Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
    Antimicrob Agents Chemother. 2020;64.

  82. LE MP, Le Beller C, Le Hingrat Q, Jaquet P, et al
    Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
    Antimicrob Agents Chemother. 2020;64.

  83. DOI Y, Hibino M, Hase R, Yamamoto M, et al
    A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available

    October 2020
  84. LE MP, Le Hingrat Q, Jaquet P, Wicky PH, et al
    Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available

  85. BUEHRLE DJ, Decker BK, Wagener MM, Adalja A, et al
    Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available

    August 2020
  86. FINTELMAN-RODRIGUES N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, et al
    Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
    Antimicrob Agents Chemother. 2020 Aug 5. pii: AAC.00825.
    PubMed     Abstract available

    January 2020
  87. BROADBENT L, Parke HG, Ferguson LJ, Millar A, et al
    Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available

  88. DEVINCENZO J, Tait D, Efthimiou J, Mori J, et al
    A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.